CHANGES IN MBS BULK BILLING INCENTIVES ADDRESS GP CAPACITY IN WOMEN’S HEALTH Reforms expand professional pathways and clinical scope to meet the demands of patients
With
Dr Sneha Wadhwani, GP
Bondi Junction Medical & Dental Centre &
Conjoint Lecturer, UNSW Medical School &
Clinical Director NSW & ACT,
Head of GP Wellbeing & Women’s Health,
ForHealth Group &
Co-Founder & National Clinical Director
Evoca Women’s Health
SEGMENT
Filmed in Sydney | November 2025
Dr. Sneha Wadhwani, a General Practitioner in Bondi, and Conjoint Lecturer at UNSW School of Medicine, is actively involved in enhancing women’s health services across Australia. As the Co-founder and Clinical Director of Evoca Women’s Health, she highlights the significant improvements in funding for women’s health, particularly with the new MBS bulk billing incentives, in new codes, that commenced on November 1, 2025.
These codes facilitate bulk billing for essential services such as menopause health assessments and long-acting reversible contraceptives, enabling more women to access critical care at little or no cost. These advancements address long-standing challenges faced by GPs, including time constraints and inadequate funding, which have historically limited comprehensive women’s health care delivery.
The investment in training for IUDs and contraceptive implants is another vital component of this initiative, equipping more GPs to provide these services effectively. Dr. Wadhwani notes that the Evoca model prioritises GP-led, holistic care, with trained practitioners working alongside allied health professionals to support women through various stages of their lives.
With the expansion of Evoca clinics from one to 43 nationally and an expectation that 75% will eventually adopt bulk billing, Dr Wadhwani believes there is a significant opportunity for GPs interested in women’s health to upskill and serve women who have previously delayed care due to costs. Dr. Wadhwani emphasises that addressing women’s health has far-reaching effects on families and communities, creating a compelling call to action for clinicians to embrace these new incentives.
Source: Adapted from transcript
-
Value of MedTech Report brings Industry and Government together
In June 2023 the Medical Technology Association of Australia (MTAA) launched The Value of MedTech Report – a major study quantifying the difference the MedTech industry makes to the lives of Australian patients, the healthcare system and the Australian economy.
Australian Health Journal spoke with MTAA CEO, Ian Burgess and MTAA Policy Manager, Pravin Siriwardena about the report and its key findings.
-
Surgical Site Infection (SSI) Synopsis, including modifiable and non-modifiable risk factors
Talking to the Australian Health Journal, Professor Russo states there is a particular concern in joint operations, such as hip or knee replacements, as infections in these areas can have severe consequences, including the removal of the infected joint, prolonged treatment, and significant costs for both hospitals and patients. Despite the substantial impact of surgical site infections, Australia lacks a national surveillance program for these infections, making it challenging to obtain accurate data. However, an estimate suggests that around 45,000 surgical site infections occur annually in Australia, resulting in approximately 900 deaths.
-
Supporting women in arthroplasty, surgery & orthopaedic oncology
Associate Professor Claudia Di Bella is an academic orthopaedic surgeon based in Melbourne, specialising in orthopaedic oncology and complex joint reconstruction. Originally trained at the world-renowned Rizzoli Orthopaedic Institute (Istituto Ortopedico Rizzoli) in Bologna, Italy, she moved to Australia in 2010 and was awarded Fellowship of the Royal Australasian College of Surgeons in 2013.
